Date | Price Target | Rating | Analyst |
---|---|---|---|
7/23/2024 | $21.00 → $19.00 | Buy → Hold | Jefferies |
11/3/2023 | $52.00 → $24.00 | Buy → Neutral | UBS |
10/13/2023 | $55.00 → $22.00 | Buy → Hold | Canaccord Genuity |
3/29/2023 | $40.00 | Buy | UBS |
2/17/2023 | Buy → Hold | Needham | |
12/21/2022 | $44.00 | Overweight | Barclays |
10/12/2022 | $40.00 | Buy | Jefferies |
2/11/2022 | $103.00 → $82.00 | Buy | Needham |
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G - InMode Ltd. (0001742692) (Subject)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
YOKNEAM, Israel, Sept. 4, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will present in-person at the 2024 Baird Global Healthcare Conference in New York on Sept. 10, 2024. The fireside chat, moderated by Jeff Johnson, Senior Research Analyst, is scheduled for 2:00 pm Eastern Time on Tuesday, Sept. 10, and a live webcast of the presentation can be accessed here. InMode will also hold one-on-one investor meetings in person that same day. To schedule a meeting, please contact your Baird representative. For more information about the event, visit InMode's investor relations
YOKNEAM, Israel, Aug. 6, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in August: 9th Annual Needham Virtual MedTech & Diagnostics Conference Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial OfficerFormat: Virtual one-on-one meetingsWhen: Monday, Aug. 12 Canaccord 44th Annual Global Growth Conference Presenters: Yair Malca, Chief Financial OfficerFormat: In-person fireside chat moderated by Caitlin
YOKNEAM, Israel, Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights: Quarterly GAAP revenue of $86.4 million, a decrease of 36.5% compared to the second quarter of 2023. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 87% of its quarterly revenues, while 6% were derived from InMode's traditional laser and non-invasive RF platforms and 7% were derived from InMode's hands-free platforms. Pro-forma revenue (includin
Jefferies downgraded InMode from Buy to Hold and set a new price target of $19.00 from $21.00 previously
UBS downgraded InMode from Buy to Neutral and set a new price target of $24.00 from $52.00 previously
Canaccord Genuity downgraded InMode from Buy to Hold and set a new price target of $22.00 from $55.00 previously
YOKNEAM, Israel, Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights: Quarterly GAAP revenue of $86.4 million, a decrease of 36.5% compared to the second quarter of 2023. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 87% of its quarterly revenues, while 6% were derived from InMode's traditional laser and non-invasive RF platforms and 7% were derived from InMode's hands-free platforms. Pro-forma revenue (includin
Believes InMode's Cash Balance of Roughly 55% of its Market Cap is Grossly Inefficient Asserts the Current Valuation Offers an Unprecedented Opportunity to Create Shareholder Return MIAMI, July 25, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC today sent a letter to the Board of Directors of InMode (NYSE: INMD) urging the Board to execute a 40% tender offer of the stock. The letter can be downloaded here. The full text of the letter follows: July 25, 2024 To the Board Members of InMode: DOMA Perpetual Capital Management is an asset manager focused on generating l
Expects Q2 Revenue Between $86.2M-$86.3M, Pro-Forma Revenue (including new platform pre-orders) Between $102.4M-$102.5M, Decreases FY 2024 Guidance to $430M-$440M Conference call to be held on Thursday, Aug. 1, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 11, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2024 before the Nasdaq market opens on Thursday, Aug. 1, 2024. InMode is currently finalizing its financial res
Jefferies analyst Matthew Taylor downgrades InMode (NASDAQ:INMD) from Buy to Hold and lowers the price target from $21 to $19.
Barclays analyst Matt Miksic maintains InMode (NASDAQ:INMD) with a Overweight and lowers the price target from $33 to $29.